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A B S T R A C T
Trans-cutaneous valve implantation (TAVI) has witnessed rapid evolution in terms of technical design,
efﬁcacy, and safety outcomes. This has led to expanding indications of TAVI from inoperable to high
surgical to now even lower surgical risk patients. However, its cost and applicability only in elderly
patients with degenerated valves is a cause of concern limiting the use of this technology. Further
evolution may lead to its application in lower risk essentially younger patients with broader etiologic
sub-groups.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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The goal of modern medicine is to ﬁght death and decrease
disease and disability. To achieve this goal, the whole ﬁeld evolves
in a way that therapy becomes more and more efﬁcacious
(prolongs life) as well as safer and less disabling. Thus, there is
an ongoing quest to make therapy less invasive and more
convenient, of course without losing any of its efﬁcacy. Thus,
there is a constant shift toward a simpler form of treatment, from
surgical to interventional to intravenous or even oral. Thus, it is not
surprising that we have seen more number of patients being
treated with percutaneous coronary interventions (PCI) than
coronary artery bypass grafting (CABG) and still more patients
being treated with medical therapy like statins or anti-anginals
than PCI. Logically, one would expect that less invasive therapy
would ﬁrst be applied in less sicker patients before being applied to
really sick ones. However, one of the principal precepts of medicine
is ‘‘Primum non nocere’’ which is a Latin phrase that means ‘‘ﬁrst,
do no harm.’’ This fundamental principle of medicine reminds the
health care provider that they must consider the possible harm
that any intervention might do even before considering the
possible beneﬁt. Its real world application in medical practice that
translates into any newer intervention/therapy being used ﬁrst in
only ‘‘no-option patients.’’ Only when beneﬁt is well established in
these patients, way beyond possible harms can the new therapy be
applied in less sicker sub-sets. Percutaneous valve therapy is no
exception. Initially applied to inoperable or high-risk surgical
patients (Society of Thoracic Surgeons score >10%, surgeon
assessed risk of mortality >15%), there is now some evidence to
suggest that patient selection for trans-cutaneous valve implanta-
tion/replacement (TAVI/TAVR) is now shifting toward lower
surgical risk patients.1,2http://dx.doi.org/10.1016/j.ihj.2016.04.019
0019-4832/ 2016 Published by Elsevier B.V. on behalf of Cardiological Society of
creativecommons.org/licenses/by-nc-nd/4.0/)2. Comparison of outcome
Over the years, there has been a gradual improvement in the
outcomes and a reduction in complication rates related to gain in
proﬁciency (overcoming the learning curve) and technological
advances in the device technology. In the surgically inoperable
group (PARTNER Trial cohort B), patients treated with TAVI had a
lower mortality rate compared with those treated only with
medications/medications and balloon aortic valvuloplasty (20.5%
vs. 44.6% mortality; hazard ratio, 0.39; 95% conﬁdence interval [CI],
0.27–0.56; P < 0.001).3 In high-risk surgical group offered surgical
aortic valve replacement (SAVR), there were no differences in
mortality at 30 days, 1-year, or 2-year follow-up (30 days – 3.4% for
the TAVI arm vs. 6.4% for the SAVR arm; 1 year – 24.2% for the TAVI
arm vs. 26.8% for the SAVR arm; 2 year – 33.9% for the TAVI arm and
35.0% for the SAVR arm).2,4 Newer devices with lower strut
thickness, better frame geometry, and lower proﬁle may have even
better outcomes. In the PARTNER II trial, the rate of death from any
cause or disabling stroke was similar in the TAVI group vs. the
surgery group at 2 years (the event rates were 19.3% in the TAVI
group vs. 21.1% in the surgery group; hazard ratio in the TAVI
group, 0.89; 95% CI, 0.73–1.09; P = 0.25). On the other hand, in sub-
group where the transfemoral-access was obtained for TAVI, the
rate of death or disabling stroke was even lower than surgery
(hazard ratio, 0.79; 95% CI, 0.62–1.00; P = 0.05).5
2.1. Valve function
Typically, oriﬁce areas are larger than comparable surgical
prostheses related to not only absence of a bulky sewing ring but
also the ability to implant oversized prostheses after balloon
dilation. Echocardiographic evaluation of both currently available India. This is an open access article under the CC BY-NC-ND license. (http://
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effective oriﬁce areas of over 1.5 cm2 in the TAVI patients.6 In the
PARTNER 2 trial, the improvements in aortic-valve areas and
gradients at all time points were signiﬁcantly greater after TAVI
than after surgery.5
2.2. Stroke rates
Stroke rates have been classically higher with TAVI than SAVR.
In the PARTNER A trial, the neurologic events, were higher with
TAVI even with femoral artery access, 4.6% vs. 1.4% for SAVR
(P = 0.05).2 The mechanism of these neurologic defects seems to be
related to release of embolic debris from degenerated aortic valve
and aorta. However, with newer low proﬁle devices, which may
cause less injury while negotiating arch of aorta this difference also
disappears. In the PARTNER 2 trial with newer balloon-expandable
SAPIEN XT1 heart-valve system, at 2 years, the rate of disabling
stroke was 6.2% after TAVI and 6.4% after surgery. Even earlier,
30 days and 1-year rates were similar.
2.3. Valvular regurgitation
Although no head-to-head comparison is available, paravalv-
ular leak (PVL) is more frequently seen after TAVI than after SAVR
(in the PARTNER trial, moderate/severe in 12% in TAVI patients’ vs.
4% in SAVR patients).1,2,7 The use of self-expandable TAVI
(CoreValve1) is one of the major determinants of signiﬁcant PVL
after TAVI. In FRANCE II registry, self-expandable prosthesis was
associated with a moderate to severe PVL rate of 19.8%, compared
with 12.2% for balloon-expandable prosthesis.8 The concern with
these regurgitant lesions is that they may not be innocuous.
Numerous studies have identiﬁed AR 2+ to be an independent
predictor of short- and long-term mortality.9 Another concern
about PVL has been potential worsening during extended follow-
up. Data from the PARTNER trial revealed mixed outcomes. At 2-
year follow-up, it increased by 1 grade in 22.4% of patients,
remained unchanged in 46.2%, and improved by 1 grade in 31.5%
of patients.10
2.4. Conduction abnormalities
Conduction abnormality is another complication which is much
higher in TAVI as compared to SAVR. While the most common
conduction disturbance is left bundle branch block but serious
conduction abnormalities requiring pacemaker implantation are
the dreaded ones.11 Three factors have been consistently
associated with new development of conduction defects: the
previous existence of right bundle branch block, self-expanding
TAVI (22% with CoreValve1 – CoreValve US Pivotal extreme risk
iliofemoral study and 3.4% with Edwards valve – PARTNER Cohort
B trial), and the deep implantation of the prosthesis.3,12
2.5. Other complications
While large number of complications can rarely occur after/
during TAVI: arterial dissection, perforation, myocardial ischemia,
and cardiogenic shock, a complication unique to this device is the
possibility of coronary obstruction by the percutaneous valve or
even native valve.13
2.6. Prosthetic valve degeneration
Structural valve degeneration (SVD) is the main cause of SAVR
failure; the reported incidence being <1% at 1-year, 10–30% at 10-
year, and 20–50% at 15 years.14 In a recent study, rate of TAVI
degeneration was 4.5% at a mean follow-up of nearly 2 years.Absence of anticoagulation therapy (at discharge), a valve-in-valve
(TAVI in a surgical valve) procedure, the use of a 23-mm valve, and
a high BMI were found predictors of SVD.
3. Current value of TAVI technology
TAVI is really an exciting technology much in tune with medical
philosophy of moving away from invasiveness to less invasive
options likely to improve quality of life. However, at the moment, it
comes at a huge cost which seems disproportionally higher than
the surgical alternative. In the current context, perhaps resource-
rich communities/developed world is better placed to experiment
and ﬁne-tune this technology. Developing world on the other hand
is focused on cost-effectiveness of a therapy and challenged with
avoiding a waste.
3.1. What is waste?
What is a medically wasteful therapy – any therapy that is often
not beneﬁcial and may cause harm and rapidly escalates cost of
healthcare. The U.S. by far wastes higher on health care than any
other country (48% higher health-care spending than next highest
spending country Switzerland but nevertheless does not appear to
achieve substantially better health benchmarks compared to other
developed countries).15 Further, the spending is not uniform,
almost half of all health care spent on just 5% of the population;
adults aged 65 and older had the highest health care spending.
Interestingly, some estimate that 30% of that price tag may be
waste: overtreatment, failures of care coordination, failures of care
delivery, administrative complexity, etc. and totally avoidable. Not
only this wasteful spending sometimes medically harmful but with
limited budgets leads to cost cuts in essential areas like preventive
medicine and care for young but also basic necessities like food and
housing. Kaiser Health Tracking Polls found that to meet growing
medical expenses 11% used up almost all their savings, many not
only used up all their savings but had to take loan and 11% were
hounded by a collection agency when they were unable to pay
their loans, and 7% reporting being unable to pay for basic
necessities like food, heat, or housing.16,17 One can imagine that
this is a situation in a market dominated by insurance what will
happen in those regions where >90% ‘‘people pay from their
pocket,’’ like India.18
3.2. Impact of age
Aging population presents both challenges and opportunities.
They can strain/drain personal and social resources but at the same
time older people are a wonderful knowledge and experience
resource not only for their families and communities but even in
the formal or informal workforce. They can help us avoid making
the same mistakes again. The societies that adapt to this changing
demography can reap a sizeable ‘‘longevity dividend’’, and will
have a competitive advantage over those that do not. Essentially all
societies practice some form of resource-transfer schemes, directly
as Social Security or indirectly through family resources. However,
shrinking working populations and enlarging elderly populations
are putting a huge strain on this classical arrangement so much so
that it even warrants novel policy decisions related to the provision
of health services for the elderly. These decisions have to
encompass new technological, ﬁscal, and ethical perspectives.
Should health care delivery be related to economic productivity? Is
there a point where you have to say ‘‘Thus far and no more?’’ Or is
differential treatment by age always an example of ‘‘age bias’’ we
should avoid as a matter of justice? On the other hand, we do treat
people differently at different ages (same guidelines/therapeutic
options in many cases do not apply to elderly). The underlying
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becomes completely healthy. But what goes wrong with our bodies
as we grow older are underlying biological processes of aging that
advance regardless of the diseases that are commonly expressed
throughout the life course. Thus, from a treatment perspective, an
elderly is always different from young and disease in them cannot
be considered an isolated event. If we extend this differentiation to
treatment options and ﬁnancial cut-offs, it should not be
inherently unfair as long as we do not create inequalities across
persons, and the same rules for different treatment apply across
their lifespan. Moreover, health in older age is not achieved in
isolation from the rest of the life course, investments now in health
at younger and middle ages are likely to yield a healthier and
longer-lived older population in the future and thus we might have
to be willing to trade away some care we might give ourselves late
in life.19 We have to focus on what makes life as a whole better for
us rather than thinking about ‘‘us’’ now vs. ‘‘them’’ now. Thus, ideal
goal of therapy in elderly should not be mere prolongation of life
but prolonging it in a way that they can remain healthy and
participative in community discourse. Indeed, if we can ensure
older people live healthier as well as longer lives, if we can make
sure that we are stretching life in the middle and not just at the
end, these extra years can be as productive as any others.
4. What lies ahead: emerging TAVI technologies
With the evolution of technology, newer generation devices
have a lower strut thickness, better frame geometry, and lower
proﬁle. Further, they may provide a better supra-, infra-, or intra-
annular sealing. Introduction of new delivery system makes them
more amenable to controlled deployment, repositioning, or
removal as also preventing deep implantation of device. Further
ﬁne-tuning the technique and developing new strategies for ‘‘bed
preparation’’ such as pre-implantation calciﬁcation debulking may
ensure adequate valve expansion and annulus sealing. Finally,
careful selection of patients and valve type may all lead to a
dramatic reduction in already low complications so much so that
TAVI may become an alternate to SAVR even in low-risk and
younger patients.
5. Evolution of TAVI technologies
Apart from a model of wasteful health-care economies fueled
primarily by insurance sector, TAVI will become really useful in
global health scenario when it will be applied to a wider population
base and in those in productive age-groups. Its real value will be
proven when patients will start paying from their own pockets. In
other words, the innovation will have to move in a way that it canbe applied to younger populations, in regurgitant lesions, for non-
degenerative sub-sets of valve diseases, and a much lower cost.
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